Puma Biotechnology (PBYI) Competitors $3.56 +0.02 (+0.56%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. AVXL, ABUS, EOLS, KALV, ANAB, COGT, ABCL, TRVI, SION, and CDXCShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), Trevi Therapeutics (TRVI), Sionna Therapeutics (SION), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Its Competitors Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences AbCellera Biologics Trevi Therapeutics Sionna Therapeutics ChromaDex Anavex Life Sciences (NASDAQ:AVXL) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership. Is AVXL or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Anavex Life Sciences' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -37.50% -34.08% Puma Biotechnology 9.56%41.60%10.71% Does the MarketBeat Community prefer AVXL or PBYI? Puma Biotechnology received 117 more outperform votes than Anavex Life Sciences when rated by MarketBeat users. However, 74.92% of users gave Anavex Life Sciences an outperform vote while only 67.43% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformAnavex Life SciencesOutperform Votes44274.92% Underperform Votes14825.08% Puma BiotechnologyOutperform Votes55967.43% Underperform Votes27032.57% Do institutionals & insiders have more ownership in AVXL or PBYI? 31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, AVXL or PBYI? Anavex Life Sciences has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Do analysts rate AVXL or PBYI? Anavex Life Sciences presently has a consensus price target of $44.00, suggesting a potential upside of 435.28%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 96.63%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anavex Life Sciences is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, AVXL or PBYI? Puma Biotechnology has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.55-14.95Puma Biotechnology$232.71M0.76$21.59M$0.774.62 Does the media refer more to AVXL or PBYI? In the previous week, Puma Biotechnology had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.45 beat Puma Biotechnology's score of 1.45 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPuma Biotechnology beats Anavex Life Sciences on 12 of the 18 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$176.69M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio7.428.6727.1819.96Price / Sales0.76262.53412.23157.63Price / Cash4.1965.8538.2534.64Price / Book3.186.597.064.69Net Income$21.59M$143.75M$3.23B$248.14M7 Day Performance-4.30%0.82%0.80%0.95%1 Month Performance18.27%12.09%9.71%5.74%1 Year Performance7.23%4.46%32.11%14.73% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology4.1402 of 5 stars$3.56+0.6%$7.00+96.6%-1.0%$176.69M$232.71M7.42200Positive NewsAVXLAnavex Life Sciences3.9254 of 5 stars$7.56+0.4%$44.00+482.0%+119.2%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.2554 of 5 stars$3.36flat$5.50+63.7%+10.2%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.1088 of 5 stars$9.97+8.5%$23.75+138.2%-11.7%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals4.0689 of 5 stars$12.92+9.5%$24.83+92.2%+6.0%$642.33MN/A-3.55100Insider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.8022 of 5 stars$21.86-1.7%$40.38+84.7%-2.9%$642.25M$111.87M-3.60100COGTCogent Biosciences2.5566 of 5 stars$5.61+3.1%$14.57+159.7%-20.1%$638.73MN/A-2.2680Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.524 of 5 stars$2.14+5.9%$8.33+289.4%-7.9%$638.63M$23.11M-3.51500Options VolumeTRVITrevi Therapeutics3.5054 of 5 stars$6.32-2.9%$18.63+194.7%+117.3%$631.32MN/A-14.3620High Trading VolumeSIONSionna TherapeuticsN/A$13.97+2.0%$38.50+175.6%N/A$616.41MN/A0.0035CDXCChromaDex2.6307 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120 Related Companies and Tools Related Companies Anavex Life Sciences Competitors Arbutus Biopharma Competitors Evolus Competitors KalVista Pharmaceuticals Competitors AnaptysBio Competitors Cogent Biosciences Competitors AbCellera Biologics Competitors Trevi Therapeutics Competitors Sionna Therapeutics Competitors ChromaDex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
